Antifungal resistance in superficial mycoses

References

• Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev. 1995;8(2):240–259.
   PubMed Web of Science ®Google Scholar
• Ananthanarayan and Paniker’s textbook of microbiology - ProQuest [Internet]. 2021. [cited 2021 Apr 19]. Available from: https://search.proquest.com/openview/904a4f8a188da6d47c05dc3a8c0a7653/1?pq-origsite=gscholar&cbl=226513
   Google Scholar
• Hazarika D, Jahan N, Sharma A. Changing trend of superficial mycoses with increasing nondermatophyte mold infection: a clinicomycological study at a tertiary referral center in Assam. Indian J Dermatol. 2019;64(4):261–265.
   PubMed Web of Science ®Google Scholar
• Warnock DW. Fungal diseases: an evolving public health challenge. Med Mycol. 2006;44(8):697–705.
   PubMed Web of Science ®Google Scholar
• Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(4):2–15.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Versteeg SG, Shear NH. Onychomycosis in the 21st century: an update on diagnosis, epidemiology, and treatment. J Cutan Med Surg. 2017;21(6):525–539.
   PubMed Web of Science ®Google Scholar
• WHO-Antimicrobial resistance [Internet]. 2021. [cited 2021 Apr 19]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
   Google Scholar
• Rammelkamp CH, Maxon T. Resistance of Staphylococcus aureus to the action of penicillin. Proc Soc Exp Biol Med. 1942;51(3):386–389.
   Google Scholar
• Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–433.
   PubMed Web of Science ®Google Scholar
• Redgrave LS, Sutton SB, Webber MA, et al. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014;22(8):438–445.
   PubMed Web of Science ®Google Scholar
• Duplessis C, Crum-Cianflone NF. Ceftaroline: a new cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). Clin Med Rev Ther. 2011;3:a2466.
   PubMedGoogle Scholar
• Burns WH, Saral R, Santos GW, et al. Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet. 1982;1(8269):421–423.
   PubMed Web of Science ®Google Scholar
• Sibrack CD, Gutman LT, Wilfert CM, et al. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis. 1982;146(5):673–682.
   PubMed Web of Science ®Google Scholar
• Erice A, Chou S, Biron KK, et al. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 1989;320(5):289–293.
   PubMed Web of Science ®Google Scholar
• Boivin G, Edelman CK, Pedneault L, et al. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis. 1994;170(1):68–75.
   PubMed Web of Science ®Google Scholar
• Lyall EG, Ogilvie MM, Smith NM, et al. Acyclovir resistant varicella zoster and HIV infection. Arch Dis Child. 1994;70(2):133–135.
   PubMed Web of Science ®Google Scholar
• Breton G, Fillet AM, Katlama C, et al. Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. Clin Infect Dis. 1998;27(6):1525–1527.
   PubMed Web of Science ®Google Scholar
• Yuen MF, Fung J, Wong DKH, et al. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis. 2009;9(4):256–264.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49(S5):S174–S84.
   PubMedGoogle Scholar
• Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30(5):1302–1306.
   PubMed Web of Science ®Google Scholar
• Schiff ER, Lai C-L, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003;38(6):1419–1427.
   PubMed Web of Science ®Google Scholar
• Carr S, Ilyushina NA, Franks J, et al. Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J. 2011;30(4):284–288.
   PubMed Web of Science ®Google Scholar
• Antiviral drug resistance among influenza viruses | CDC [Internet]. 2019. [cited 2021 Apr 20]. Available from: https://www.cdc.gov/flu/professionals/antivirals/antiviral-drug-resistance.htm
   Google Scholar
• Sterling TR, Merz WG. Resistance to amphotericin B: emerging clinical and microbiological patterns. Drug Resist Updat. 1998;1(3):161–165.
   PubMed Web of Science ®Google Scholar
• Boschman CR, Bodnar UR, Tornatore MA, et al. Thirteen-year evolution of Azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob Agents Chemother. 1998;42(4):734–738.
   PubMed Web of Science ®Google Scholar
• Ghannoum M. Azole resistance in dermatophytes: prevalence and mechanism of action. J Am Podiatr Med Assoc. 2016;106(1):79–86.
   PubMed Web of Science ®Google Scholar
• Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure1. Emerg Infect Dis. 2009;15(7):1068–1076.
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Leidich SD, Isham N, et al. Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother. 2003;47(1):82–86.
   PubMed Web of Science ®Google Scholar
• Singh A, Masih A, Khurana A, et al. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018;61(7):477–484.
   PubMed Web of Science ®Google Scholar
• Mazzantini D, Celandroni F, Calvigioni M, et al. In Vitro resistance and evolution of resistance to tavaborole in Trichophyton rubrum. Antimicrob Agents Chemother. 2021;65(4):e02324–20.
   PubMed Web of Science ®Google Scholar
• Monti D, Mazzantini D, Tampucci S, et al. Ciclopirox and efinaconazole transungual permeation, antifungal activity, and proficiency to induce resistance in Trichophyton rubrum. Antimicrob Agents Chemother. 2019;63(0):e00442–19.
   PubMedGoogle Scholar
• Subissi A, Monti D, Togni G, et al. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs. 2010;70(16):2133–2152.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Renaud HJ, Quinlan EM, et al. The growing problem of antifungal resistance in onychomycosis and other superficial mycoses. Am J Clin Dermatol. 2021;22(2):149–157.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Luo W, Verweij PE, et al. Regional differences in antifungal susceptibility of the prevalent dermatophyte Trichophyton rubrum. Mycopathologia. 2021;186(1):53–70.
   PubMed Web of Science ®Google Scholar
• Antifungal resistance | fungal diseases | CDC [Internet]. 2020. [cited 2021 Apr 19]. Available from: https://www.cdc.gov/fungal/antifungal-resistance.html
   Google Scholar
• Marichal P, Koymans L, Willemsens S, et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (Reading). 1999;145:2701–2713.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Isham N. Fungal nail infections (onychomycosis): a never-ending story? PLoS Pathog. 2014;10(6):e1004105.
   PubMed Web of Science ®Google Scholar
• Pai V, Ganavalli A, Kikkeri NN. Antifungal resistance in dermatology. Indian J Dermatol. 2018;63(5):361–368.
   PubMed Web of Science ®Google Scholar
• Crawford F, Young P, Godfrey C, et al. Oral treatments for toenail onychomycosis: a systematic review. Arch Dermatol. 2002;138:811–816.
   PubMed Web of Science ®Google Scholar
• Santos HL, Lang EAS, Segato F, et al. Terbinafine resistance conferred by multiple copies of the salicylate 1-monooxygenase gene in Trichophyton rubrum. Med Mycol. 2018;56(3):378–381.
   PubMed Web of Science ®Google Scholar
• Poojary S, Miskeen A, Bagadia J, et al. A study of in vitro antifungal susceptibility patterns of dermatophytic fungi at a tertiary care center in Western India. Indian J Dermatol. 2019;64(4):277–284.
   PubMed Web of Science ®Google Scholar
• Thakur R, Kalsi AS. Outbreaks and epidemics of superficial dermatophytosis due to trichophyton mentagrophytes complex and Microsporum canis: global and Indian Scenario. Clin Cosmet Investig Dermatol. 2019;12:887–893.
   PubMed Web of Science ®Google Scholar
• Singh A, Masih A, Monroy-Nieto J, et al. A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: genomic insights and resistance profile. Fungal Genet Biol. 2019;133(103266):103266.
   PubMedGoogle Scholar
• Kano R, Kimura U, Kakurai M, et al. Trichophyton indotineae sp. nov.: a new highly terbinafine-resistant anthropophilic dermatophyte species. Mycopathologia. 2020;185(6):947–958.
   PubMed Web of Science ®Google Scholar
• Tang C, Kong X, Ahmed SA, et al. Taxonomy of the trichophyton mentagrophytes/T. interdigitale species complex harboring the highly virulent, multiresistant genotype T. indotineae. Mycopathologia. 2021. DOI:10.1007/s11046-021-00544-2.
   Web of Science ®Google Scholar
• Yamada T, Maeda M, Alshahni MM, et al. Terbinafine resistance of Trichophyton clinical isolates caused by specific point mutations in the squalene epoxidase gene. Antimicrob Agents Chemother. 2017;61(7):e00115–17.
   PubMed Web of Science ®Google Scholar
• Ebert A, Monod M, Salamin K, et al. Alarming India-wide phenomenon of antifungal resistance in dermatophytes: a multicentre study. Mycoses. 2020;63(7):717–728.
   PubMed Web of Science ®Google Scholar
• Hsieh A, Quenan S, Riat A, et al. A new mutation in the SQLE gene of Trichophyton mentagrophytes associated to terbinafine resistance in a couple with disseminated tinea corporis. J Mycol Med. 2019;29(4):352–355.
   PubMed Web of Science ®Google Scholar
• Salehi Z, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Antifungal drug susceptibility profile of clinically important dermatophytes and determination of point mutations in terbinafine-resistant isolates. Eur J Clin Microbiol Infect Dis. 2018;37(10):1841–1846.
   PubMed Web of Science ®Google Scholar
• Verma S, Madhu R. The great Indian epidemic of superficial dermatophytosis: an appraisal. Indian J Dermatol. 2017;62(3):227–236.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Mano Y, Furuya N, et al. Discovery of terbinafine low susceptibility Trichophyton rubrum strain in Japan. Biocontrol Sci. 2018;23(3):151–154.
   PubMed Web of Science ®Google Scholar
• Saunte D, Pereiro-Ferreirós M, Rodríguez-Cerdeira C, et al. Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic. J Eur Acad Dermatol Venereol. 2021;35(7):1582–1586.
   PubMed Web of Science ®Google Scholar
• Gaurav V, Bhattacharya SN, Sharma N, et al. Terbinafine resistance in dermatophytes: time to revisit alternate antifungal therapy. J Mycol Med. 2021;31(1):101087.
   PubMed Web of Science ®Google Scholar
• Ksiezopolska E, Gabaldón T. Evolutionary emergence of drug resistance in Candida opportunistic pathogens. Genes (Basel). 2018;9(9):461.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Chowdhary A, Melchers WJG, et al. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62(3):362–368.
   PubMed Web of Science ®Google Scholar
• Mellado E, Alcazar-Fuoli L, García-Effrón G, et al. New resistance mechanisms to azole drugs in Aspergillus fumigatus and emergence of antifungal drugs-resistant A. fumigatus atypical strains. Med Mycol. 2006;44(1):S367–S71.
   PubMedGoogle Scholar
• Chowdhary A, Sharma C, Hagen F, et al. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol. 2014;9(5):697–711.
   PubMed Web of Science ®Google Scholar
• Forsberg K, Woodworth K, Walters M, et al. Candida auris: the recent emergence of a multidrug-resistant fungal pathogen. Med Mycol. 2019;57(1):1–12.
   PubMed Web of Science ®Google Scholar
• Beardsley J, Halliday CL, Chen SC-A, et al. Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside. Future Microbiol. 2018;13:1175–1191.
   PubMed Web of Science ®Google Scholar
• Chen E, Ghannoum M, Elewski BE. Treatment-resistant tinea corporis, a potential public health issue. Br J Dermatol. 2021;184(1):164–165.
   PubMed Web of Science ®Google Scholar
• Gu D, Hatch M, Ghannoum M, et al. Treatment-resistant dermatophytosis: a representative case highlighting an emerging public health threat. JAAD Case Rep. 2020;6(11):1153–1155.
   PubMedGoogle Scholar
• Nofal A, Fawzy MM, El-Hawary EE. Successful treatment of resistant onychomycosis with voriconazole in a liver transplant patient. Dermatol Ther. 2020;33:e14014.
   PubMed Web of Science ®Google Scholar
• Schøsler L, Andersen LK, Arendrup MC, et al. Recurrent terbinafine resistant Trichophyton rubrum infection in a child with congenital ichthyosis. Pediatr Dermatol. 2018;35(2):259–260.
   PubMed Web of Science ®Google Scholar
• Al-Hatmi AMS, Bonifaz A, Calderón L, et al. Proximal subungual onychomycosis caused by Fusarium falciforme successfully cured with posaconazole. Br J Dermatol. 2015;173(1):253–255.
   PubMed Web of Science ®Google Scholar
• Kumar S, Kaur A, Kaur S. Autoimplantation therapy in extensive and recalcitrant dermatophytosis: a case series. J Clin Aesthet Dermatol. 2021;14(1):34–37.
   PubMedGoogle Scholar
• Farowski F, Vehreschild JJ, Cornely OA. Posaconazole: a next-generation triazole antifungal. Future Microbiol. 2007;2(3):231–243.
   PubMed Web of Science ®Google Scholar
• Abastabar M, Hosseini T, Valadan R, et al. Novel point mutations in cyp51A and cyp51B genes associated with itraconazole and posaconazole resistance in Aspergillus clavatus isolates. Microb Drug Resist. 2019;25(5):652–662.
   PubMed Web of Science ®Google Scholar
• Hivary S, Fatahinia M, Halvaeezadeh M, et al. The potency of luliconazole against clinical and environmental Aspergillus nigri complex. Iran J Microbiol. 2019;11(6):510–519.
   PubMed Web of Science ®Google Scholar
• Hivary S, Fatahinia M, Halvaeezadeh M, et al. Luliconazole, a new antifungal, vs. amphotericin B, voriconazole, posaconazole and caspofungin against clinical and environmental Aspergillus nigri complex. bioRxiv. 2019.
   Google Scholar
• Yamaguchi H. Potential of ravuconazole and its prodrugs as the new oral therapeutics for onychomycosis. Med Mycol J. 2016;57(4):E93– E110.
   PubMedGoogle Scholar
• Kano R, Hiruma J, Yokota M, et al. In Vitro ravuconazole susceptibility of anthropophilic dermatophyte strains isolated from Japanese patients. Jpn J Infect Dis. 2020;73(3):250–252.
   PubMed Web of Science ®Google Scholar
• Abastabar M, Haghani I, Shokohi T, et al. Low in vitro antifungal activity of tavaborole against yeasts and moulds from onychomycosis. Antimicrob Agents Chemother. 2018;62(0):e01632–18.
   PubMedGoogle Scholar
• Baghi N, Shokohi T, Badali H, et al. In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates. Med Mycol. 2016;54(7):757–763.
   PubMed Web of Science ®Google Scholar
• Shimoyama H, Satoh K, Makimura K, et al. Epidemiological survey of onychomycosis pathogens in Japan by real-time PCR. Med Mycol. 2019;57(6):675–680.
   PubMed Web of Science ®Google Scholar
• Sahni K, Singh S, Dogra S. Newer topical treatments in skin and nail dermatophyte infections. Indian Dermatol Online J. 2018;9(3):149–158.
   PubMedGoogle Scholar
• General information | MRSA | CDC [Internet]. 2019. [cited 2021 Apr 19]. Available from: https://www.cdc.gov/mrsa/community/index.html
   Google Scholar
• Fattahi A, Shirvani F, Ayatollahi A, et al. Multidrug-resistant Trichophyton mentagrophytes genotype VIII in an Iranian family with generalized dermatophytosis: report of four cases and review of literature. Int J Dermatol. 2021;60(6):686–692.
   PubMedGoogle Scholar
• Süß A, Uhrlaß S, Ludes A, et al. [Extensive tinea corporis due to a terbinafine-resistant Trichophyton mentagrophytes isolate of the Indian genotype in a young infant from Bahrain in Germany]. Hautarzt. 2019;70(11):888–896.
   PubMed Web of Science ®Google Scholar
• Das S, De A, Saha R, et al. The current Indian epidemic of dermatophytosis: a study on causative agents and sensitivity patterns. Indian J Dermatol. 2020;65(2):118–122.
   PubMed Web of Science ®Google Scholar
• Marquez L, Quave CL. Prevalence and therapeutic challenges of fungal drug resistance: role for plants in drug discovery. Antibiotics (Basel). 2020;9(4):150. [cited 2021 Apr 19] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235788/
   PubMed Web of Science ®Google Scholar
• Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383–92–e392.
   Web of Science ®Google Scholar
• Dong J, Liang G, Zheng H, et al. In Vitro activity of ravuconazole against Candida auris and vaginal candida isolates. Mycoses. 2021;64:651–655.
   PubMed Web of Science ®Google Scholar
• Dogra S, Shaw D, Rudramurthy SM. Antifungal drug susceptibility testing of dermatophytes: laboratory findings to clinical implications. Indian Dermatol Online J. 2019;10(3):225–233.
   PubMedGoogle Scholar
• Rezaei-Matehkolaei A, Khodavaisy S, Alshahni MM, et al. In Vitro antifungal activity of novel triazole efinaconazole and five comparators against dermatophyte isolates. Antimicrob Agents Chemother. 2018;62(5):e02423–17.
   PubMed Web of Science ®Google Scholar
• Badali H, Mohammadi R, Mashedi O, et al. In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs. Mycoses. 2015;58(5):303–307.
   PubMed Web of Science ®Google Scholar
• Alexander BD. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. 2017.
   Google Scholar
• Arendrup MC, Kahlmeter G, Guinea J, et al. Subcommittee on antifungal susceptibility testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). How to: perform antifungal susceptibility testing of microconidia-forming dermatophytes following the new reference EUCAST method E.Def 11.0, exemplified by Trichophyton. Clin Microbiol Infect. 2021;27(1):55–60.
   PubMed Web of Science ®Google Scholar
• Shaw D, Singh S, Dogra S, et al. Upper limit of wild-type distribution for 13 antifungal agents against a Trichophyton mentagrophytes-Trichophyton interdigitale complex of Indian origin. Antimicrob Agents Chemother. 2020;64(4):e01964–19.
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Jørgensen KM, Guinea J, et al. Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. J Antimicrob Chemother. 2020;75(7):1807–1819.
   PubMed Web of Science ®Google Scholar
• EUCAST: Breakpoints for antifungals [Internet]. 2021. [cited 2021 Apr 19]. Available from: https://eucast.org/astoffungi/clinicalbreakpointsforantifungals/
   Google Scholar
• Gupta AK, Taborda V, Taborda P, et al. High prevalence of mixed infections in global onychomycosis. PLoS One. 2020;15(9):e0239648.
   PubMed Web of Science ®Google Scholar
• Sugiura K, Masumoto A, Tachibana H, et al. In Vitro combination effect of topical and oral anti-onychomycosis drugs on Trichophyton rubrum and trichophyton interdigitale. J Fungi (Basel). 2021;7(3):208.
   PubMedGoogle Scholar
• Gupta AK, Venkataraman M, Renaud Hj Summerbell R, et al. The increasing problem of treatment-resistant fungal infections: a call for antifungal stewardship programs. Int J Dermatol. 2021. DOI:10.1111/ijd.15495.
   Web of Science ®Google Scholar